NKTR Drug delivery Company Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NKTR Drug delivery Company

NKTR 55.97

+1.5%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: ghmm who wrote (415)	10/1/2018 12:50:36 PM
From: Miljenko Zuanic	Read Replies (1) of 507

< the premise of it increasing TIL's and providing synergy with other mechanisms has not been disapproved> Yes, TILs proliferation and increase in PD1 expressed CD8+ T cells is what count in combination. My problem is that ,yet, there is no explanation (From NKTR or BMY) on *excessive* decline in response rate from cohort expansion PIVOT trial???? (RCC and melanoma)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next